Critical aspects to be considered prior to large-scale production of peptides

Current Protein and Peptide Science

Volumn 14, Issue 7, 2013, Pages 556-567

  Mulder, Kelly Cristina Leite ^a   Viana, Antônio Américo Barbosa ^a   Xavier, Mauro ^c,d   Parachin, Nádia Skorupa ^a,b  

^a UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^d VALLÉE S A   (Brazil)

Author keywords

Calcitonin; Chemical synthesis; Fuzeon; Glucagon; Heterologous expression; Pexiganan; Sandostatin; Scale up

Indexed keywords

CALCITONIN; ENFUVIRTIDE; GLATIRAMER; GLUCAGON; GOSERELIN; GUANIDINE; HUMAN INSULIN; INDIUM 111; LEUPRORELIN; LUTETIUM 177; OCTREOTIDE; PARATHYROID HORMONE; PRAMLINTIDE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GLUCAGON; SALCATONIN; SOMATOSTATIN; TROPONIN C; YTTRIUM 90;

ACROMEGALY; AMINO ACID SEQUENCE; ARTICLE; BIOMASS; BONE ATROPHY; FACE MALFORMATION; FERMENTATION; FERMENTATION OPTIMIZATION; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; GOOD MANUFACTURING PRACTICE; GROWTH RATE; HUMAN; HYPOGLYCEMIA; INFLAMMATION; LARGE SCALE PRODUCTION; NAUSEA; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PAGET BONE DISEASE; PEPTIDE SYNTHESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PURIFICATION; RECOMBINANT DNA TECHNOLOGY; SCALE UP; UNSPECIFIED SIDE EFFECT;

BLOOD GLUCOSE; BONE RESORPTION; GENETIC ENGINEERING; GROWTH HORMONE; HIV; HUMANS; PEPTIDES;

EID: 84888216625     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/13892037113149990071     Document Type: Article

References (136)

1. Hopkins, F. G.; Dixon, M. On glutathione. II. A thermostable oxidation-reduction system. J. Biol. Chem., 1992, 54, 527-563.
2. Du Vigneaud, V.; Ressler, C.; Trippett, S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J. Biol. Chem., 1953, 205(2), 949-957.
3. Merrifield, R. B. Solid Phase Peptide Synthesis.1. Synthesis of a Tetrapeptide. J. Am. Chem. Soc., 1963, 85(14), 2149-2154.
4. Power, O.; Jakeman, P.; Fitzgerald, R. J. Antioxidative peptides: enzymatic production, in vitro and in vivo antioxidant activity and potential applications of milk-derived antioxidative peptides. Amino Acids, 2013, 44(3), 797-820.
5. Escudero, E.; Aristoy, M. C.; Nishimura, H.; Arihara, K.; Toldra, F. Antihypertensive effect and antioxidant activity of peptide fractions extracted from Spanish dry-cured ham. Meat Sci., 2012, 91(3), 306-311.
6. Okubo, B. M.; Silva, O. N.; Migliolo, L.; Gomes, D. G.; Porto, W. F.; Batista, C. L.; Ramos, C. S.; Holanda, H. H.; Dias, S. C.; Franco, O. L.; Moreno, S. E. Evaluation of an antimicrobial Lamino acid oxidase and peptide derivatives from Bothropoides mattogrosensis pitviper venom. PloS one, 2012, 7(3), e33639.
7. Tavares, L. S.; Rettore, J. V.; Freitas, R. M.; Porto, W. F.; Duque, A. P.; Singulani, J. D.; Silva, O. N.; Detoni, M. D.; Vasconcelos, E. G.; Dias, S. C.; Franco, O. L.; Santos, M. D. Antimicrobial activity of recombinant Pg-AMP1, a glycine-rich peptide from guava seeds. Peptides, 2012, 37(2), 294-300.
8. Pinto, M. F.; Fensterseifer, I. C.; Migliolo, L.; Sousa, D. A.; de Capdville, G.; Arboleda-Valencia, J. W.; Colgrave, M. L.; Craik, D. J.; Magalhaes, B. S.; Dias, S. C.; Franco, O. L. Identification and structural characterization of novel cyclotide with activity against an insect pest of sugar cane. J. Biol. Chem., 2012, 287(1), 134-147.
9. Silva, O. N.; Porto, W. F.; Migliolo, L.; Mandal, S. M.; Gomes, D. G.; Holanda, H. H.; Silva, R. S.; Dias, S. C.; Costa, M. P.; Costa, C. R.; Silva, M. R.; Rezende, T. M.; Franco, O. L. Cn-AMP1: a new promiscuous peptide with potential for microbial infections treatment. Biopolymers, 2012, 98(4), 322-331.
10. Zeng, M. Y.; Cui, W. X.; Zhao, Y. H.; Liu, Z. Y.; Dong, S. Y.; Guo, Y. Antiviral active peptide from oyster. Chin. J. Oceanol. Limnol., 2008, 26(3), 307-312.
11. Kannan, A.; Hettiarachchy, N. S.; Lay, J. O.; Liyanage, R. Human cancer cell proliferation inhibition by a pentapeptide isolated and characterized from rice bran. Peptides, 2010, 31(9), 1629-1634.
12. Hancock, R. E.; Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol., 2006, 24(12), 1551-1557.
13. Marx, V. Watching peptide drugs grow up. Chemical & Engineering News, 2005, 83(11), 17-24.
14. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: science and market. Drug Discov. Today, 2010, 15(1-2), 40-56.
15. Agyei, D.; Danquah, M. K. Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides. Biotechnol. Adv., 2011, 29(3), 272-277.
16. Bundgaard, H. The Utility of the Prodrug Approach to Improve Peptide Absorption. J. Controlled Release, 1992, 21(1-3), 63-72.
17. Antosova, Z.; Mackova, M.; Kral, V.; Macek, T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol., 2009, 27(11), 628-635.
18. Sato, A. K.; Viswanathan, M.; Kent, R. B.; Wood, C. R. Therapeutic peptides: technological advances driving peptides into development. Curr. Opin. Biotechnol., 2006, 17(6), 638-642.
19. Pichereau, C.; Allary, C. Therapeutic Peptides under the Spotlight. European BioPharmaceutical Review, 2005, 5.
20. Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D. The future of peptide-based drugs. Chemical biology & drug design, 2013, 81(1), 136-147.
21. Lax, R. The Future of Peptide Development in the Pharmaceutical Industry. PharManufacturing: The International Peptide Review, 2010, 10-15.
22. Reichert, J.; Pechon, P.; Tartar, A.; Dunn, M. K. 2010 Report Summary: Development trends for peptide therapeutics. Peptide Therapeutic Foundation, 2010, 1-11.
23. Bray, B. L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov., 2003, 2(7), 587-593.
24. Thayer, A. M. Making Peptides At Large Scale. Chem. Eng. News, 2011, 89(22), 21-25.
25. Bruckdorfer, T.; Marder, O.; Albericio, F. From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Curr. Pharm. Biotechnol., 2004, 5(1), 29-43.
26. Kent, S. B. Total chemical synthesis of proteins. Chemical Soc. Rev., 2009, 38(2), 338-351.
27. Kent, S. B. Chemical Peptide Synthesis in the Development of Protein Therapeutics. PharManufacturing: The Inter. Pep. Rev., 2010, 16-21.
28. Parachin, N. S.; Mulder, K. C.; Viana, A. A. B.; Dias, S. C.; Franco, O. L. Expression Systems for Heterologous Production of Antimicrobial Peptides. Peptides, 2012, 38(2), 446-456.
29. Viana, A. A. B.; Pelegrini, P. B.; Grossi-de-Sá, M. F. Plant biofarming: Novel insights for peptide expression in heterologous systems. Biopolymers, 2012, 98(4), 416-427.
30. Li, Y.; Chen, Z. RAPD: a database of recombinantly-produced antimicrobial peptides. FEMS Microbiol. Lett., 2008, 289(2), 126-129.
31. Conley, A. J.; Jevnikar, A. M.; Menassa, R.; Brandle, J. E. Temporal and spatial distribution of erythropoietin in transgenic tobacco plants. Transgenic Res., 2010, 19(2), 291-298.
32. Hennegan, K.; Yang, D.; Nguyen, D.; Wu, L.; Goding, J.; Huang, J.; Guo, F.; Huang, N.; Watkins, S. C. Improvement of human lysozyme expression in transgenic rice grain by combining wheat (Triticum aestivum) puroindoline b and rice (Oryza sativa) Gt1 promoters and signal peptides. Transgenic Res., 2005, 14(5), 583-592.
33. Jiang, X. R.; Zhou, X. Y.; Jiang, W. Y.; Gao, X. R.; Li, W. L. Expression of thermostable bacterial cellulases in tobacco plant. Biotechnol. Lett., 2011, 33(9), 1797-1803.
34. Rubio-Infante, N.; Govea-Alonso, D. O.; Alpuche-Solis, A. G.; Garcia-Hernandez, A. L.; Soria-Guerra, R. E.; Paz-Maldonado, L. M.; Ilhuicatzi-Alvarado, D.; Varona-Santos, J. T.; Verdin-Teran, L.; Korban, S. S.; Moreno-Fierros, L.; Rosales-Mendoza, S. A chloroplast-derived C4V3 polypeptide from the human immunodeficiency virus (HIV) is orally immunogenic in mice. Plant Mol. Biol., 2012, 78(4), 337-349.
35. Saumonneau, A.; Rottier, K.; Conrad, U.; Popineau, Y.; Gueguen, J.; Francin-Allami, M. Expression of a new chimeric protein with a highly repeated sequence in tobacco cells. Plant Cell Rep., 2011, 30(7), 1289-1302.
36. Chance, R. E.; Frank, B. H. Research, development, production, and safety of biosynthetic human insulin. Diabetes care, 1993, 16 (3), 133-142.
37. Ghaderi, D.; Zhang, M.; Hurtado-Ziola, N.; Varki, A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol. Genet. Eng. Rev., 2012, 28, 147-175.
38. Huang, C. J.; Lin, H.; Yang, X. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J. Ind. Microbiol. Biotechnol., 2012, 39(3), 383-399.
39. Mattanovich, D.; Branduardi, P.; Dato, L.; Gasser, B.; Sauer, M.; Porro, D. Recombinant protein production in yeasts. Methods Mol. Biol., 2012, 824, 329-358.
40. Chen, X.; Zhu, F.; Cao, Y.; Qiao, S. Novel expression vector for secretion of cecropin AD in Bacillus subtilis with enhanced antimicrobial activity. Antimicrob. Agents Chemother., 2009, 53(9), 3683-3689.
41. Esposito, D.; Chatterjee, D. K. Enhancement of soluble protein expression through the use of fusion tags. Curr. Opin. Biotechnol., 2006, 17(4), 353-358.
42. Hamilton, S. R.; Davidson, R. C.; Sethuraman, N.; Nett, J. H.; Jiang, Y.; Rios, S.; Bobrowicz, P.; Stadheim, T. A.; Li, H.; Choi, B. K.; Hopkins, D.; Wischnewski, H.; Roser, J.; Mitchell, T.; Strawbridge, R. R.; Hoopes, J.; Wildt, S.; Gerngross, T. U. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science, 2006, 313(5792), 1441-1443.
43. Huether, C. M.; Lienhart, O.; Baur, A.; Stemmer, C.; Gorr, G.; Reski, R.; Decker, E. L. Glyco-engineering of moss lacking plantspecific sugar residues. Plant Biol (Stuttg), 2005, 7(3), 292-299.
44. Koprivova, A.; Stemmer, C.; Altmann, F.; Hoffmann, A.; Kopriva, S.; Gorr, G.; Reski, R.; Decker, E. L. Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans. Plant Biotechnol. J., 2004, 2(6), 517-523.
45. Li, H.; Sethuraman, N.; Stadheim, T. A.; Zha, D.; Prinz, B.; Ballew, N.; Bobrowicz, P.; Choi, B. K.; Cook, W. J.; Cukan, M.; Houston-Cummings, N. R.; Davidson, R.; Gong, B.; Hamilton, S. R.; Hoopes, J. P.; Jiang, Y.; Kim, N.; Mansfield, R.; Nett, J. H.; Rios, S.; Strawbridge, R.; Wildt, S.; Gerngross, T. U. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol., 2006, 24(2), 210-215.
46. Thayer, A. M. Making Peptides At Large Scale. Chemical & Engineering News, 2011, 89(22), 21-25.
47. Amblard, M.; Fehrentz, J. A.; Martinez, J.; Subra, G. Methods and protocols of modern solid phase Peptide synthesis. Mol. Biotechnol., 2006, 33(3), 239-254.
48. Guzmán, F.; Barberis, S.; Illanes, A. Peptide synthesis: chemical or enzymatic. Electron. J. Biotechnol., 2007, 10(2), 279-314.
49. Andersson, D. I. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol., 2006, 9(5), 461-465.
50. Andersson, L.; Blomberg, L.; Flegel, M.; Lepsa, L.; Nilsson, B.; Verlander, M. Large-scale synthesis of peptides. Biopolymers, 2000, 55(3), 227-250.
51. Junker, B. H. Scale-up methodologies for Escherichia coli and yeast fermentation processes. J. Biosci. Bioeng., 2004, 97(6), 347-364.
52. Kilikian, B. V.; Suarez, I. D.; Liria, C. W.; Gombert, A. K. Process strategies to improve heterologous protein production in Escherichia coli under lactose or IPTG induction. Process Biochem., 2000, 35(9), 1019-1025.
53. Ramchuran, S. O.; Holst, O.; Karlsson, E. N. Effect of postinduction nutrient feed composition and use of lactose as inducer during production of thermostable xylanase in Escherichia coli glucoselimited fed-batch cultivations. J. Biosci. Bioeng., 2005, 99(5), 477-484.
54. Gombert, A. K.; Kilikian, B. V. Recombinant gene expression in Escherichia coli cultivation using lactose as inducer. J. Biotechnol., 1998, 60(1-2), 47-54.
55. Neubauer, P.; Hofmann, K.; Holst, O.; Mattiasson, B.; Kruschke, P. Maximizing the expression of a recombinant gene in Escherichia coli by manipulation of induction time using lactose as inducer. Appl. Microbiol. Biotechnol., 1992, 36(6), 739-744.
56. Menzella, H. G.; Ceccarelli, E. A.; Gramajo, H. C. Novel escherichia coli strain allows efficient recombinant protein production using lactose as inducer. Biotechnol. Bioeng., 2003, 82(7), 809-817.
57. Kim, E. K.; Moon, J. C.; Lee, J. M.; Jeong, M. S.; Oh, C.; Ahn, S. M.; Yoo, Y. J.; Jang, H. H. Large-scale production of soluble recombinant amyloid-beta peptide 1-42 using cold-inducible expression system. Protein Expression Purif., 2012, 86(1), 53-57.
58. Yang, J.; Yang, C.; Jiang, H.; Qiao, C. Overexpression of methyl parathion hydrolase and its application in detoxification of organophosphates. Biodegradation, 2008, 19(6), 831-839.
59. Donovan, R. S.; Robinson, C. W.; Glick, B. R. Review: optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter. J. Ind. Microbiol., 1996, 16(3), 145-154.
60. Cserjan-Puschmann, M.; Grabherr, R.; Striedner, G.; Clementschitsch, F.; Bayer, K. Optimizing recombinant microbial fermentation processes. BioPharm., 2002.
61. Shojaosadati, S. A.; Kolaei, S. M. V.; Babaeipour, V.; Farnoud, A. M. Recent advances in high cell density cultivation for production of recombinant protein. Iran. J. Biotechnol., 2008, 6(2), 63-84.
62. Ramerez, D. M.; Bentley, W. E. Enhancement of recombinant protein synthesis and stability via coordinated amino acid addition. Biotechnol. Bioeng., 1993, 41(5), 557-565.
63. th 2013).
64. th 2012).
65. Thiry, M.; Cingolani, D. Optimizing scale-up fermentation processes. Trends Biotechnol., 2002, 20(3), 103-105.
66. Schmidt, F. R. Optimization and scale up of industrial fermentation processes. Appl. Microbiol. Biotechnol., 2005, 68(4), 425-435.
67. Sen, R.; Swaminathan, T. Response surface modeling and optimization to elucidate and analyze the effects of inoculum age and size on surfactin production. Biochem. Eng. J., 2004, 21(2), 141-148.
68. Monaghan, R. L.; Gagliardi, M. M.; Streicher, S. L. in: Demain, A. L.; Davies, J. E. Culture preservation and inoculum development, manual of industrial microbiology and biotechnology. ASM Press: Washington, D.C., 1999, 29-48.
69. Ganguly, S.; Banik, A. K. Optimization of physical conditions for the production of L-glutamic acid by a mutant Micrococcus glutamicus AB100. Intern. J. Pharma Bio. Sci., 2011, 2, 295-299.
70. Okonkowski, J.; Kizer-Bentley, L.; Listner, K.; Robinson, D.; Chartrain, M. Development of a robust, versatile, and scalable inoculum train for the production of a DNA vaccine. Biotechnol. Prog., 2005, 21(4), 1038-1047.
71. Alba, M. J. G.; Calvo, E. G. Characterization of bioreaction processes: Aerobic Escherichia coli cultures. J. Biotechnol., 2000, 84, 107-118.
72. Riesenberg, D.; Guthke, R. High-cell-density cultivation of microorganisms. Appl. Microbiol. Biotechnol., 1999, 51(4), 422-30.
73. Kim, B. S.; Lee, S. C.; Lee, S. Y.; Chang, Y. K.; Chang, H. N. High cell density fed-batch cultivation of Escherichia coli using exponential feeding combined with pH-stat. Bioprocess Biosyst. Eng., 2004, 26(3), 147-50.
74. Korz, D. J.; Rinas, U.; Hellmuth, K.; Sanders, E. A.; Deckwer, W. D. Simple fed-batch technique for high cell density cultivation of Escherichia coli. J. Biotechnol., 1995, 39(1), 59-65.
75. Kleman, G. L.; Strohl, W. R. Developments in high cell density and high productivity microbial fermentation. Curr. Opin. Biotechnol., 1994, 5(2), 180-186.
76. Panda, A. K.; Khan, R. H.; Rao, K. B.; Totey, S. M. Kinetics of inclusion body production in batch and high cell density fed-batch culture of Escherichia coli expressing ovine growth hormone. J. Biotechnol., 1999, 75(2-3), 161-172.
77. Khalilzadeh, R.; Shojaosadati, S. A.; Bahrami, A.; Maghsoudi, N. Fed-batch cultivation of recombinant Escherichia coli producing human interferon-γ under controlled specific growth rate. Iran. J. Biotechnol., 2004, 2, 113-122.
78. Babaeipour, V.; Shojaosadati, S. A.; Robatjazi, S. M.; Khalilzadeh, R.; Maghsoudi, N. Over-production of human interferon-g by HCDC of recombinant Escherichia coli. Process Biochem., 2007, 42, 112-117.
79. Riesenberg, D.; Schulz, V.; Knorre, W. A.; Pohl, H. D.; Korz, D.; Sanders, E. A.; Ross, A.; Deckwer, W. D. High cell density cultivation of Escherichia coli at controlled specific growth rate. J. Biotechnol., 1991, 20(1), 17-27.
80. Choi, J. H.; Keum, K. C.; Lee, S. Y. Production of recombinant proteins by high cell density culture of Escherichia coli. Chem Eng Sci, 2006, 61, 876-885.
81. Jung, G.; Denefle, P.; Becquart, J.; Mayaux, J. F. High-cell density fermentation studies of recombinant Escherichia coli strains expressing human interleukin-1 beta. Ann. Inst. Pasteur. Microbiol., 1988, 139(1), 129-146.
82. Khalilzadeh, R.; Shojaosadati, S. A.; Bahrami, A.; Maghsoudi, N. Over-expression of recombinant human interferon-gamma in high cell density fermentation of Escherichia coli. Biotechnol. Lett., 2003, 25(23), 1989-1992.
83. Akesson, M.; Hagander, P.; Axelsson, J. P. Avoiding acetate accumulation in Escherichia coli cultures using feedback control of glucose feeding. Biotechnol. Bioeng., 2001, 73(3), 223-230.
84. Aristidou, A. A.; San, K. Y.; Bennett, G. N. Modification of central metabolic pathway in escherichia coli to reduce acetate accumulation by heterologous expression of the bacillus subtilis acetolactate synthase gene. Biotechnol. Bioeng., 1994, 44(8), 944-951.
85. Silva, F.; Queiroz, J. A.; Domingues, F. C. Plasmid DNA fermentation strategies: influence on plasmid stability and cell physiology. Appl. Microbiol. Biotechnol., 2012, 93(6), 2571-2580.
86. Pouliot, K.; Tibault, J.; Garnier, A.; Leiva, G. A. KLa evaluation of the course of fermentation using data reconciliation techiniques. Bioprocess Eng., 2000, 23, 565-573.
87. Lee, S. Y. High cell-density culture of Escherichia coli. Trends Biotechnol., 1996, 14(3), 98-105.
88. Belo, I.; Mota, M. Batch and fed-batch cultures of E-coli TB1 at different oxygen transfer rates-Effect of stirring and oxygen partial pressures on cell growth and cytochrome b5 production. Bioprocess Eng., 1998, 18(6), 451-455.
89. de Mare, L.; Velut, S.; Ledung, E.; Cimander, C.; Norrman, B.; Karlsson, E. N.; Holst, O.; Hagander, P. A cultivation technique for E. coli fed-batch cultivations operating close to the maximum oxygen transfer capacity of the reactor. Biotechnol. Lett., 2005, 27(14), 983-990.
90. Jahic, M.; Wallberg, F.; Bollok, M.; Garcia, P.; Enfors, S.-O. Temperature limited fed-batch technique for control of proteolysis in Pichia pastoris biorreactor cultures. Microb. cell fact., 2003, 2, 6-17.
91. Wigley, A.; Wilkinson, D.; Mead, D. A. Managing scale up of recombinant proteins. Automatic feed control for the production of Pharmaceutical-grade Proteins. Genetic Engin. Biotechnol. News, 2007, 27(2), 1-1.
92. Holmes, W. J.; Darby, R. A.; Wilks, M. D.; Smith, R.; Bill, R. M. Developing a scalable model of recombinant protein yield from Pichia pastoris: the influence of culture conditions, biomass and induction regime. Microb. cell fact., 2009, 8(35), 1-14.
93. Vasquez-Alvarez, E.; Lienqueo, M. E.; Pinto, J. M. Optimal synthesis of protein purification processes. Biotechnol. Prog., 2001, 17(4), 685-696.
94. Johnson, I. S. Human insulin from recombinant DNA technology. Science, 1983, 219, 632-637.
95. Ayoub, M.; Scheidegger, D. Peptide drugs, overcoming the challenges, a growing business. Chim Oggi, 2006, 24(4), 46-48.
96. Inzerillo, A. M.; Zaidi, M.; Huang, C. L. Calcitonin: physiological actions and clinical applications. J. Pediatric Endocri. Metabol., JPEM, 2004, 17(7), 931-40.
97. Zaidi, M.; Inzerillo, A. M.; Moonga, B. S.; Bevis, P. J. R.; Huang, C. L.-H. Forty Years of Calcitonin-Where Are We Now? A Tribute to the Work of Iain Macintyre, FRS. Bone Marrow Transplant., 2002, 30(5), 655-663.
98. Kirk, J. K.; Hepfinger, C. Calcitonin. Clin. Rev. Bone. Miner. Metab., 2005, 3(1), 39-49.
99. Plosker, G. L.; McTavish, D. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging, 1996, 8(5), 378-400.
100. Ishikawa, H.; Kawaguchi, J.; Yao, Y.; Tamaoki, H.; Ono, T.; Fukui, F.; Yoshikawa, H. Large-scale preparation of recombinant human calcitonin from a multimeric fusion protein produced in Escherichia coli. J. Biosci. Bioeng., 1999, 87(3), 296-301.
101. Ishikawa, H.; Tamaoki, H. Production of human calcitonin in Escherichia coli from multimeric fusion protein. J. Ferment. Bioeng., 1996, 82(2), 140-144.
102. Hong, B.; Wu, B. Y.; Li, Y. Production of C-terminal amidated recombinant salmon calcitonin in Streptomyces lividans. Appl. Biochem. Biotechnol., 2003, 110(2), 113-123.
103. Dilsen, S.; Paul, W.; Sandgathe, A.; Tippe, D.; Freudl, R.; Thommes, J.; Kula, M. R.; Takors, R.; Wandrey, C.; Weuster-Botz, D. Fed-batch production of recombinant human calcitonin precursor fusion protein using Staphylococcus carnosus as an expressionsecretion system. Appl. Microbiol. Biotechnol., 2000, 54(3), 361-369.
104. Emisphere Technologies. Salmon Calcitocin for Osteoarthritis and Osteoporosis. http://www.emisphere.com/salmon_calcitonin.html (Accessed November 12, 2004).
105. Tarsa Therapeutics. Tarsa therapeutics signs commercial supply agreement for its ostora™ oral calcitonin product with qs pharma. http://www.tarsatherapeutics.com/News/032112.html (Accessed December 4, 2004).
106. Tas, C.; Mansoor, S.; Kalluri, H.; Zarnitsyn, V. G.; Choi, S. O.; Banga, A. K.; Prausnitz, M. R. Delivery of salmon calcitonin using a microneedle patch. Int. J. Pharm., 2012, 423(2), 257-263.
107. Bomanji, J. B.; Papathanasiou, N. D. (1)(1)(1)In-DTPA(0)-octreotide (Octreoscan), (1)(3)(1)I-MIBG and other agents for radionuclide therapy of NETs. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(1), 113-125.
108. Liu, Y. Development of labelled somatostatin and its analogues for the diagnosis and treatment of tumors. J. Radioana. Nuclear Chem., 1996, 206(1), 171-184.
109. Bodei, L.; Cremonesi, M.; Grana, C. M.; Chinol, M.; Baio, S. M.; Severi, S.; Paganelli, G. Yttrium-labelled peptides for therapy of NET. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(1), 93-102.
110. Kam, B. L.; Teunissen, J. J.; Krenning, E. P.; de Herder, W. W.; Khan, S.; van Vliet, E. I.; Kwekkeboom, D. J. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(1), 103-112.
111. Lamberts, S. W.; Krenning, E. P.; Reubi, J. C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev., 1991, 12(4), 450-82.
112. Lamberts, S. W. J.; van der Lely, A.-J.; de Herder, W. W.; Hofland, L. J. Octreotide. New Engl. J. Med., 1996, 334(4), 246-254.
113. Susini, C.; Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol., 2006, 17(12), 1733-1742.
114. Jane, J. A., Jr.; Thapar, K.; Laws, E. R., Jr. Acromegaly: historical perspectives and current therapy. J. Neuro-oncol., 2001, 54(2), 129-137.
115. Melmed, S. Acromegaly. New Engl. J. Med., 2006, 355(24), 2558-2573.
116. Rivier, J.; Brazeau, P.; Vale, W.; Guillemin, R. Somatostatin analogs. Relative importance of the disulfide bridge and of the Ala-Gly side chain for biological activity. J. Med. Chem., 1975, 18(2), 123-126.
117. Veber, D. F.; Holly, F. W.; Nutt, R. F.; Bergstrand, S. J.; Brady, S. F.; Hisrschmann, R.; Glitzer, M. S.; Saperstein, R. Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature, 1979, 280(5722), 512-514.
118. Bauer, W.; Briner, U.; Doepfner, W.; Haller, R.; Huguenin, R.; Marbach, P.; Petcher, T. J.; Pless. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci., 1982, 31(11), 1133-1140.
119. Murlin, J. R.; Clough, H. D.; Gibbs, C. B. F.; Stokes, A. M. Aqueous extracts of pancreas. J. Biol. Chem., 1923, 56(1), 253-296.
120. Sutherland, E. W.; De Duve, C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J. Biol. Chem., 1948, 175(2), 663-674.
121. Collens, W. S.; Murlin, J. R. Hyperglycemia Following the Portal Injection of Insulin. Proceedings of the Society for Experimental Biology and Medicine. Soc. Exp. Biol. Med., (New York, N.Y.), 1929, 26(6), 485-490.
122. Staub, A.; Sinn, L.; Behrens, O. K. Pufification and crystallization of glucagon. J. Biol. Chem., 1955, 214(2), 619-632.
123. Jiang, G.; Zhang, B. B. Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metabol., 2003, 284(4), 671-678.
124. Bell, G. I.; Sanchez-Pescador, R.; Laybourn, P. J.; Najarian, R. C. Exon duplication and divergence in the human preproglucagon gene. Nature, 1983, 304(5924), 368-371.
125. Ardill, J. E. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Annals of Clinic. Biochem., 2008, 45(Pt 6), 539-559.
126. Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev., 2007, 87(4), 1409-39.
127. Aman, J.; Wranne, L. Hypoglycaemia in childhood diabetes. II. Effect of subcutaneous or intramuscular injection of different doses of glucagon. Acta paediatrica Scandinavica, 1988, 77(4), 548-553.
128. Yoshikawa, K.; Tsuzuki, H.; Fujimoto, M.; Tohkin, M.; Matsubara, T.; Yonezawa, H.; Okamoto, H.; Teraoka, H.; Yoshida, N. Recombinant human glucagon: Large-scale purification and biochemical characterization. J. Protein Chem., 1992, 11(5), 517-525.
129. Okamoto, H.; Iwamoto, H.; Tsuzuki, H.; Teraoka, H.; Yoshida, N. An improved method for large-scale purification of recombinant human glucagon. J. Protein Chem., 1995, 14(7), 521-526.
130. Egel-Mitani, M.; Andersen, A. S.; Diers, I.; Hach, M.; Thim, L.; Hastrup, S.; Vad, K. Yield improvement of heterologous peptides expressed in yps1-disrupted Saccharomyces cerevisiae strains. Enzyme Microb. Technol., 2000, 26(9-10), 671-677.
131. Fonjallaz, P.; Loumaye, E. Glucagon rDNA origin (GlucaGen®) and Recombinant LH: (No. 12 in a series of articles to promote a better understanding of the use of genetic engineering). J. Biotechnol., 2000, 79(2), 185-189.
132. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nature Reviews Drug Discovery, 2004, 3(3), 215-225.
133. Schneider, S. E.; Bray, B. L.; Mader, C. J.; Friedrich, P. E.; Anderson, M. W.; Taylor, T. S.; Boshernitzan, N.; Niemi, T. E.; Fulcher, B. C.; Whight, S. R.; White, J. M.; Greene, R. J.; Stoltenberg, L. E.; Lichty, M. Development of HIV fusion inhibitors. J. Pept. Sci., 2005, 11(11), 744-753.
134. Marx, V. Roche's Fuzeon Challenge. Chem. Eng. News, 2005, 83(11), 16-17.
135. LaBonte, J.; Lebbos, J.; Kirkpatrick, P. Enfuvirtide. Nat. Rev. Drug Discov., 2003, 2(5), 345-346.
136. Berger, E.; Crampton, M. C.; Nxumalo, N. P.; Louw, M. E. Extracellular secretion of a recombinant therapeutic peptide by Bacillus halodurans utilizing a modified flagellin type III secretion system. Microbial. cell factories, 2011, 10(62), 1-10.